2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Anita D’Souza, MD, discusses forming a treatment strategy for patients with relapsed light chain amyloidosis.
Anita D’Souza, MD, an associate professor at the Medical College of Wisconsin, discusses forming a treatment strategy for patients with relapsed light chain (AL) amyloidosis.
Knowing when to begin treatment for patients with relapsed amyloidosis continues to be a challenge faced in clinical practice, according to D'Souza. The question of whether it is best to begin treatment as soon as biochemical numbers begin to rise or once signs of organ deterioration are observed still needs to be addressed.
Research from investigators in Italy has revealed certain factors that can be taken into consideration that can help inform treatment decisions, D’Souza says. Beginning treatment early, prior to organ deterioration has been associated with positive outcomes in this patient population, D’Souza concludes.